

First rabbit based client project started

September 14 2016 - Memo Therapeutics made it to the top 100 of Swiss startups for the second time in a row and is within the **top 10 biotech** companies. See entire list of companies.



About the TOP 100 STARTUP AWARD: Each year, startup.ch launches the TOP 100 STARTUP AWARD. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts.

About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.